This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.
CADTH. Dual antiplatelet therapy and enoxaparin or unfractionated heparin for patients with ST-elevation myocardial infarction: a review of the clinical evidence. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). 2012
No relevant studies were identified that compared the clinical effectiveness of dual antiplatelet therapy combined with enoxaparin or unfractionated heparin versus thrombolytic therapy in patients with ST-elevation myocardial infarction.
Subject indexing assigned by CRD
Enoxaparin; Heparin; Myocardial Infarctions; Platelet Aggregation Inhibitors
Country of organisation
An English language summary is available.
Address for correspondence
Canadian Agency for Drugs and Technologies in Health (CADTH), 865 Carling Avenue, Suite 600, K1S 5S8 Ottawa, Ontario Canada Email: email@example.com
Date abstract record published